OncoMatch/Clinical Trials/NCT05200260
Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer
Is NCT05200260 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including PARP inhibitor and Bevacizumab for ovarian cancer.
Treatment: PARP inhibitor · Bevacizumab — Optimal Timing of Surgery combined with Maintenance Therapy in the Front-line Treatment of Advanced Ovarian Cancer
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Ovarian Cancer
Biomarker criteria
Required: BRCA1 any tested
Required: BRCA2 any tested
Disease stage
Required: Stage IIIC, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Lab requirements
Blood counts
white blood cells >3,000/µl, absolute neutrophil count ≥1,500/µl, platelets ≥100,000/µl, hemoglobin ≥9 g/dl
Kidney function
serum creatinine <1.25 x upper normal limit (unl) or creatinine clearance ≥60 ml/min according to cockroft-gault formula or to local lab measurement
Liver function
serum bilirubin <1.25 x unl, ast(sgot) and alt(sgpt) <2.5 x unl
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05200260 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require BRCA1?
Yes, BRCA1 any tested is a required biomarker for enrollment.
Does this trial require BRCA2?
Yes, BRCA2 any tested is a required biomarker for enrollment.
What disease stage is eligible?
Stage IIIC or IV is required.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages